Why this isn't a straightforward comparison

"Which is better — ChondroFiller™ or PRP?" is a reasonable question, but the evidence cannot answer it directly, because the two treatments do not compete for the same job.

ChondroFiller™ is an injectable collagen scaffold: placed into a focal cartilage defect under image guidance, it provides a structural matrix that the body uses to generate new repair tissue. PRP is an intra-articular injection of concentrated platelets that releases growth factors to reduce local inflammation and create a more favourable biological environment in the joint. One fills a structural void; the other modifies the joint's biology. Framing them as like-for-like alternatives is a category error.

No head-to-head randomised controlled trial has directly compared them for focal cartilage defects — and that gap in the literature reflects, at least in part, the difficulty of designing a meaningful trial between interventions that operate at entirely different levels. Which treatment is appropriate, or whether both might play a role at different points in the pathway, depends on the defect characteristics identified at assessment, not on preference alone. That distinction shapes everything that follows.

What ChondroFiller™ is and how it works

ChondroFiller™ is a collagen-based scaffold — an acellular gel composed of murine-derived Type I collagen — delivered into a focal cartilage defect through an image-guided injection at a single outpatient appointment.

Once placed, the scaffold acts as a three-dimensional framework inside the defect. The mechanism is chemotactic: the gel draws the patient's own progenitor (repair) cells into the space, where they settle, multiply, and differentiate into hyaline-like tissue over a maturation period that published clinical series describe as spanning roughly 12 to 24 months. MRI data from European studies show progressive improvement in defect filling from early follow-up through to 12 months and beyond, reflecting a gradual biological process rather than an immediate structural change.

Because the scaffold is acellular — it contains no donor or laboratory-grown cells — the treatment does not require a prior harvesting or cell-preparation stage. That makes it a single-stage pathway: one appointment, rather than the two-stage sequence required by cell-based alternatives such as autologous chondrocyte implantation.

Published evidence indicates ChondroFiller is suited to contained, full-thickness focal chondral defects broadly corresponding to ICRS or Outerbridge grade III–IV and up to approximately 6 cm² in area. Precise placement is clinically important: a 2025 prospective study (Demmer et al., PMC12498443) found that defects filled flush with the surrounding surface healed well, while overfilled defects were associated with fibrous rather than hyaline-like tissue formation.

What PRP is and where it fits

Prepared from a small sample of the patient's own blood — spun in a centrifuge to concentrate the platelet fraction — PRP (Platelet-Rich Plasma) is an intra-articular injection that delivers a high concentration of growth factors directly into the joint space. Those growth factors act on the local biological environment: they reduce pro-inflammatory cytokines and create a growth-factor-rich milieu that can, for some patients, translate into pain relief and improved function.

Crucially, PRP does not provide a structural scaffold or fill a physical void in damaged cartilage. Its mechanism is environmental rather than architectural — it modifies the conditions inside the joint without replacing lost tissue.

The strongest clinical evidence for PRP in cartilage-related conditions covers knee osteoarthritis and early focal chondropathy. A 2015 clinical review by Marmotti et al. (PMC4436454, cited 135 times) concluded that PRP may be helpful both as an adjuvant to surgical cartilage repair procedures and as a standalone symptomatic therapy — framing it primarily as an enhancer of the biological milieu rather than a source of structural repair. Evidence for PRP as a primary treatment for isolated full-thickness focal defects, as distinct from osteoarthritis or early-stage chondral change, remains sparse.

Preparation protocols also vary between providers — in platelet concentration, leucocyte content, and activation method — and this variability contributes to the inconsistency in outcomes reported across published studies.

What the evidence actually shows for each

Published data on ChondroFiller™ comes primarily from European observational studies and case series. Across four reported knee studies, functional scores on the IKDC scale improved by approximately 30 points — consistently clearing the published minimal clinically important difference of 16.7 points. The Jerosch et al. prospective post-market clinical follow-up study reported a mean gain of 32.4 IKDC points, reaching an average functional score of 80, with those gains sustained and slightly increased at three-year review. MRI-based MOCART scores in the low-to-mid 80s in European studies reflect good defect filling and tissue integration; one study recorded progressive improvement from MOCART 65.3 at four weeks to 81.6 at twelve months, consistent with gradual biological maturation rather than immediate structural change.

A 2025 prospective study by Demmer et al. (PMC12498443) extended this evidence to small-joint cartilage, reporting statistically superior cartilage quality in ChondroFiller-treated patients at follow-up: a median Outerbridge score of 1.5 versus 3.0 in a comparator group (p=0.006). These findings are encouraging, though the overall evidence base remains largely observational and, in parts, sponsor-supported; large independent randomised trials are absent, and durability data beyond five years is limited.

For PRP, the documented benefit in cartilage-related conditions centres on knee osteoarthritis and early focal chondropathy. Marmotti et al.'s 2015 review (PMC4436454, cited 135 times) concluded that PRP may help both as an adjuvant to surgical cartilage procedures and as a symptomatic therapy in its own right. Evidence for PRP as a primary treatment for isolated full-thickness focal defects — as distinct from osteoarthritis — remains sparse and underpowered. Because each body of evidence addresses a different clinical target, placing the two treatments on a single performance scale is not something the available literature supports.

Which treatment suits which patient

The practical selection logic starts with imaging — specifically, what the defect actually looks like on MRI — rather than with a preference between injections.

For patients with a confirmed full-thickness focal chondral defect, typically graded ICRS or Outerbridge III to IV, the clinical aim is structural: to fill the void with a material that can support tissue regeneration from within. ChondroFiller™ is designed for that role, suited to contained lesions up to approximately 6 cm². Defect size, the condition of the surrounding cartilage, and overall joint health all bear on whether the scaffold is appropriate — which is why individual assessment matters rather than a blanket rule.

PRP addresses a different clinical picture. Where the main issue is symptomatic joint inflammation, early focal chondropathy rather than a discrete full-thickness void, or mild-to-moderate osteoarthritis, an intra-articular PRP injection may provide meaningful symptomatic and anti-inflammatory benefit without requiring structural scaffold placement. PRP also has a documented role as a biological adjunct to cartilage repair — supporting the joint environment alongside other treatments rather than replacing them.

The two pathways are not mutually exclusive. A patient presenting with a focal full-thickness defect alongside broader OA-related joint inflammation may be a candidate for a staged approach — for example, addressing joint inflammation before or after scaffold placement — where their clinical picture supports it. Decisions of this kind depend on a full clinical and imaging review; neither treatment has a fixed universal indication, and presentations vary considerably.

An MRI assessment remains the essential first step. Once imaging defines the nature and depth of the defect, the most appropriate pathway becomes considerably clearer than any general comparison can make it.

Evidence gaps and questions worth asking

The most honest summary is that both treatments carry genuine unknowns — and those unknowns are patient-relevant, not merely academic.

For ChondroFiller™, the strongest published follow-up reaches three years: long enough to confirm that functional gains are sustained rather than transient, but not long enough to answer what a younger patient with a focal defect most wants to know — whether the repair tissue is still holding at ten or fifteen years. That question remains genuinely open, and any source that answers it with confidence is going beyond what the data currently supports.

For PRP, the gap is narrower but equally practical: whether intra-articular PRP offers meaningful benefit for an isolated full-thickness focal defect — as distinct from osteoarthritis or early chondropathy — has not been rigorously established in that specific patient group.

Neither gap invalidates either treatment; both define what a clinical assessment needs to resolve for each patient individually. Useful questions to raise at that conversation:

• What grade and size is the defect on imaging?
• Is this a contained focal lesion, or is there wider joint degeneration alongside it?
• Is the aim structural repair, or principally symptom management?
• Would a staged approach be relevant given the full clinical picture?

An image-guided assessment — including MRI review — is the appropriate way to move from general comparison to individual suitability. An assessment on amsk.co.uk is the right starting point for finding out whether you may be a candidate.